Anna Yordanova

Sigmund Freud Str. 25
Bonn, NW 53127, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Combination Therapies with PRRT.

Combination Therapies with PRRT.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 27, 2021

An Impressive Approach in Nuclear Medicine: Theranostics.

An Impressive Approach in Nuclear Medicine: Theranostics.

Journal: PET clinics

Published: May 31, 2021

Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders.

Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders.

Journal: PET clinics

Published: May 31, 2021

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.

The impact of the extent of the bone involvement on overall survival and toxicity in mCRPC patients receiving [177Lu]Lu-PSMA-617: a WARMTH multicentre study.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 13, 2020

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.

Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors.

Journal: Journal of clinical medicine

Published: September 30, 2020

Bench-to-Bedside Theranostics in Nuclear Medicine.

Bench-to-Bedside Theranostics in Nuclear Medicine.

Journal: Current pharmaceutical design

Published: November 02, 2019

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases.

Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases.

Journal: International journal of endocrinology

Published: September 24, 2019

The value of tumor markers in men with metastatic prostate cancer undergoing [177 Lu]Lu-PSMA therapy.

The value of tumor markers in men with metastatic prostate cancer undergoing [177 Lu]Lu-PSMA therapy.

Journal: The Prostate

Published: May 27, 2019

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors.

Journal: Clinical nuclear medicine

Published: April 02, 2019

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer.

Journal: European journal of nuclear medicine and molecular imaging

Published: July 27, 2018

The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.

The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 26, 2018

Theranostics in nuclear medicine practice.

Theranostics in nuclear medicine practice.

Journal: OncoTargets and therapy

Published: October 19, 2017

Showing 1-12 of 29

Last Updated: 09/26/2026